Abivax is currently conducting seven clinical trials to test the tolerability, safety and efficacy of its two product candidates ABX464 and ABX196.

The ongoing clinical trials conducted with ABX464 in ulcerative colitis (UC) and rheumatoid arthritis (RA) consist each of two parts, an induction phase and a subsequent maintenance phase.

Phase 2b clinical trials in ulcerative colitis

The Phase 2b study is conducted to evaluate the efficacy and the safety of 3 different doses of ABX464, taken orally once daily by patients with moderate-to-severe ulcerative colitis. On clinicaltrials.gov you can find more information about the study and a list of study centers where the trials are being conducted.
The Phase 2b study is currently open for the recruitment of patients.

Maintenance Study

Only patients who conclude the “induction phase” of a study have the possibility to roll over into the “maintenance phase”, where long-term effects of the treatment are evaluated. As the Phase 2a induction study in UC is closed for recruitment, no more patients can be enrolled in the corresponding Phase 2a maintenance phase.

Phase 2a clinical trials in rheumatoid arthritis

The induction study aims at investigating the safety and tolerability of 2 different doses of ABX464 taken orally once daily in combination with methotrexate. The trial is conducted in patients with moderate-to-severe active rheumatoid arthritis who had an inadequate response to methotrexate or/and to one or more anti-tumor necrosis factor alpha (TNFα) therapies. On clinicaltrials.gov you can find more information about the study and a list of study centers where the trials are being conducted.
The Phase 2a study is currently open for the recruitment of patients.

Maintenance Study

Only patients who conclude the “induction phase” of a study have the possibility to roll over into the “maintenance phase”, where long-term effects of the treatment are evaluated.

Phase 1/2 clinical trial in hepatocellular carcinoma

This study evaluates the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma (HCC). On clinicaltrials.gov you can find more information about the study and a list of study centers where the trial is being conducted.
This Phase 1/2 study is currently open for the recruitment of patients.

More Information

More information can be found on clinicaltrials.gov.

Important Information

Please note that the drug candidates ABX464 and ABX196 are at present in the clinical testing stage and subject to the regulations set by the competent authorities.

Abivax is legally not entitled to decide whether a patient is eligible to be included in the clinical trials that Abivax sponsors. The investigating physicians of the clinical study centers are the sole individuals competent for deciding whether a patient is eligible, according to the inclusion and exclusion criteria defined in the corresponding clinical study protocol.

Additionally, Abivax cannot communicate or interact with individual patients on the conduct or progress of the study. You will find all publicly available information under clinicaltrials.gov.